<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964402</url>
  </required_header>
  <id_info>
    <org_study_id>IB2018-SAMPLE-SIZE-SURVIVAL</org_study_id>
    <nct_id>NCT03964402</nct_id>
  </id_info>
  <brief_title>Sample Size for Multivariate Time-to-event Data</brief_title>
  <official_title>Sample Size Determination in Heterogeneous Populations for Multivariate Time-to-event Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of randomized clinical trials (RCT) using time-to-event criteria as the primary endpoint
      are designed, powered and analyzed based on an hypothetical hazard ratio (HR) corresponding
      to the targeted effect size between experimental and control arms. Usually, one assumes that
      populations are homogeneous within each treatment arm, that is, within each arm, (i) the
      baseline risk is identical for all patients, and (ii) the treatment effect is identical for
      all patients. This assumption however may not hold in all circumstances. This project aims at
      providing a statistical method for the estimation of sample size in RCT, in the presence of
      heterogenous populations, such as assuming populations with distinct underlying baseline
      risks or assuming different treatment effects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>time from randomization to death</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Clinical Trials</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Control arm, i.e., as per standard procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>Experimental arm, i.e. investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intervention treatment</intervention_name>
    <description>intervention treatment (any)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        to be adapted to the indication under investigation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  not applicable

        Exclusion Criteria:

          -  not applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carine Bellera, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié, Comprehensive Cancer Center</name>
      <address>
        <city>Bordeaux</city>
        <zip>33400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sample size, survival, randomized clinical trials, statistical test</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

